ikbkb
immun
defici
rare
lifethreaten
primari
immunodefici
disord
involv
activ
defect
adapt
innat
immun
present
sixteen
case
homozyg
ikbkb
mutat
infant
character
earlyonset
bacteri
viral
fungal
mycobacteri
infect
case
tand
bcell
quantit
normal
phenotyp
sever
hypogammaglobulinemia
tcell
receptor
excis
circl
normal
mean
newborn
screen
trec
analysi
would
miss
ikbkb
case
although
ikbkb
immun
defici
meet
tradit
laboratori
base
definit
scid
combin
immun
defici
appear
least
profound
urgent
hsct
perform
eight
patient
remain
known
cur
therapi
although
three
patient
survivor
ongo
infect
transplant
remain
concern
may
due
combin
poor
social
determin
health
secondari
graft
failur
failur
hsct
replac
nonhematopoiet
cell
import
immun
function
depend
upon
pathway
canadian
provinc
manitoba
group
period
manag
young
infant
northern
cree
first
nation
aborigin
descent
present
earlyonset
lifethreaten
viral
bacteri
mycobacteri
fungal
infect
clinic
resembl
sever
combin
immun
defici
scid
infant
initi
identifi
two
small
northern
manitoba
commun
later
year
infant
neighbor
provinc
saskatchewan
also
identifi
group
collabor
identifi
genet
defect
four
patient
due
homozyg
duplic
mutat
exon
ikbkb
gene
encod
inhibitor
nuclear
factor
kappa
b
kinas
subunit
beta
also
known
homozyg
ikbkb
duplic
mutat
seen
popul
result
complet
loss
express
critic
compon
canon
ikknuclear
factor
kappa
b
pathway
normal
signal
tumor
necrosi
famili
receptor
tolllik
receptor
antigen
receptor
tand
bcell
induc
activ
ikk
complex
consist
kinas
well
regulatori
protein
nuclear
factor
kappab
essenti
modifi
nemo
activ
ikk
complex
specif
phosphoryl
inhibitori
protein
result
releas
cytoplasm
free
influenc
transloc
nucleu
induc
transcript
multitud
immun
inflammatori
gene
given
central
role
pathway
regul
innat
adapt
immun
respons
surpris
patient
mutat
gene
pathway
manifest
primari
immunodefici
disord
male
hypomorph
hemizyg
mutat
ikbkg
encod
nemo
protein
result
reduc
nemo
express
present
combin
immun
defici
includ
enorm
allel
immunolog
clinic
heterogen
patient
hypermorph
gain
function
mutat
nfkbia
result
reduc
degrad
protein
also
shown
exhibit
signific
combin
immun
defici
furthermor
pathway
oper
hematopoiet
nonhematopoiet
cell
lead
extraimmun
find
seen
patient
defect
nemo
ectoderm
dysplasia
coliti
similar
patient
ikbkg
nfkbia
mutat
first
four
patient
report
group
defici
due
ikbkb
mutat
also
present
immun
defici
sinc
six
addit
patient
variou
ethnic
background
includ
turkey
qatar
arabian
peninsula
differ
nonsens
ikbkb
mutat
report
patient
present
earli
onset
profound
combin
immun
defici
typic
without
find
ectoderm
dysplasia
initi
report
patient
normal
nearnorm
number
tand
bcell
almost
exclus
phenotyp
sever
hypogammaglobulinemia
activ
defect
varieti
stimuli
number
immun
cell
innat
adapt
suggest
global
function
defect
oppos
quantit
lymphocyt
defici
herein
describ
clinic
present
immunolog
featur
hsct
outcom
largest
cohort
infant
ikbkb
immun
defici
result
complet
loss
express
publish
date
studi
protocol
approv
health
research
ethic
board
univers
manitoba
author
identifi
known
genet
confirm
highli
suspect
infant
ikbkb
mutat
manag
depart
pediatr
winnipeg
children
hospit
cancercar
manitoba
manitoba
blood
marrow
transplant
program
date
data
collect
retrospect
chart
review
includ
clinic
present
immunolog
featur
hsct
approach
outcom
although
data
complet
patient
diagnos
contemporari
era
data
avail
variabl
patient
young
infant
northern
cree
descent
known
affect
commun
present
clinic
pictur
consist
sever
immun
defici
without
genet
confirm
ikbkb
mutat
consid
highli
suspect
also
close
famili
relationship
genet
confirm
infant
mutat
eg
sibl
seconddegre
rel
known
consanguin
within
famili
chose
report
decad
diagnosi
instead
year
provid
reader
perspect
immunolog
investig
treatment
avail
time
protect
potenti
inadvert
identifi
individu
given
patient
famili
resid
small
commun
detail
famili
tree
document
consanguin
relationship
within
famili
includ
reason
patient
laboratori
valu
includ
absolut
lymphocyt
count
tcell
count
bcell
count
nkcell
count
immunoglobulin
level
compar
publish
ageadjust
variabl
laboratori
paramet
describ
low
normal
high
respect
rang
matern
engraft
tcell
assess
analysi
short
tandem
repeat
use
ampf
profil
pcr
amplif
kit
life
technolog
chimer
analysi
hsct
perform
tcell
bcell
myeloid
cell
label
monoclon
antibodi
separ
use
autom
immunomagnet
cell
separ
method
robosep
instrument
stemcel
technolog
due
potenti
pauciti
cell
chimer
test
puriti
variou
lymphocyt
myeloid
subset
evalu
assay
valid
experi
howev
puriti
separ
subset
error
around
lineag
specif
chimer
result
tcell
prolif
respons
use
pha
perform
hthymidin
incorpor
assay
peripher
blood
mononuclear
cell
stimul
pha
follow
cultur
percentag
normal
pha
respons
measur
stimul
index
patient
rel
averag
stimul
index
two
concurr
run
healthi
adult
control
sampl
trec
analysi
perform
time
diagnosi
n
either
done
local
laboratori
n
clinic
laboratori
mayo
clinic
laboratori
n
unit
measur
trec
whole
blood
copiesmillion
pbmc
copiesmillion
cell
chang
time
sanger
sequenc
exon
ikbkb
perform
local
genet
per
method
develop
pannick
sampl
contain
homozyg
g
insert
within
region
interest
classifi
affect
confirm
sanger
sequenc
independ
laboratori
sixteen
patient
genet
confirm
n
highli
suspect
n
ikbkb
mutat
includ
tabl
genet
confirm
five
infant
highli
suspect
ikbkb
immun
defici
possibl
sinc
die
dna
avail
born
year
ikbkb
mutat
known
one
patient
diagnos
immedi
birth
direct
ikbkb
mutat
analysi
guthri
card
part
target
newborn
screen
project
start
novemb
two
heavili
affect
commun
patient
younger
sibl
later
diagnos
inutero
due
known
famili
histori
confirm
mutat
birth
sibl
place
protect
isol
proceed
hsct
month
age
fourteen
patient
present
health
care
facil
sever
infect
median
month
age
rang
week
month
twelv
patient
came
provinc
manitoba
four
provinc
saskatchewan
four
patient
previous
report
less
detail
initi
report
ikbkb
immun
defici
includ
patient
order
describ
addit
clinic
immunolog
characterist
provid
updat
longterm
outcom
detail
number
type
infect
present
time
initi
present
hsct
complet
twelv
incomplet
two
patient
die
dissemin
mycobacterium
bovisbacillu
calmetteguerin
bcg
patient
die
unknown
sepsi
two
sibl
identifi
newborn
screen
famili
histori
infect
time
diagnosi
ikbkb
immun
defici
proceed
urgent
hsct
without
infect
patient
identifi
newborn
screen
clinic
present
consist
multitud
sever
bacteri
fungal
mycobacteri
viral
infect
begin
earli
age
month
usual
associ
failur
thrive
mucocutan
infect
oropharynx
perineum
candida
common
n
evid
dissemin
candida
infect
tabl
clinic
present
outcom
ikbkb
immun
defici
scid
suspect
sinc
ikbkb
mutat
yet
describ
diagnosi
never
confirm
multiorgan
failur
present
hct
candid
die
hct
blood
n
urin
n
cerebrospin
fluid
n
three
sever
recurr
gramneg
gramposit
bacteri
infect
frequent
includ
bacteremia
sepsi
episod
escherichia
coli
n
pseudomona
aeruginosa
n
klebsiella
pneumonia
n
enterococcu
speci
n
staphylococcu
aureu
n
stenotrophomona
maltophilia
n
serratia
marcescen
n
streptococcu
pneumonia
n
staphylococcu
homini
n
listeria
monocytogen
n
morganella
morganni
n
leuconostoc
lacti
n
enterobact
cloaca
n
intracrani
infect
present
six
infant
includ
combin
staphylococcu
aureu
candida
albican
mening
one
listeria
monocytogen
mening
enterococcu
mening
klebsiella
pneumonia
mening
serratia
marcescen
intracerebr
abscess
mycobacterium
bovi
mening
intracerebr
abscess
five
dissemin
viral
infect
occur
cytomegaloviru
n
adenoviru
n
varicella
n
herp
simplex
viru
n
sever
pneumonia
syndrom
document
eleven
result
unknown
pathogen
n
cytomegaloviru
n
respiratori
syncyti
viru
n
polymicrobi
gram
neg
bacteria
n
adenoviru
n
rhinoviru
n
parainfluenza
n
consist
standard
practic
two
affect
commun
time
four
infant
receiv
bcg
vaccin
birth
develop
dissemin
bcg
die
biopsi
n
autopsi
n
reveal
mycobacterium
bovi
multipl
organ
includ
lung
liver
spleen
lymph
node
thymu
bone
marrow
adren
gland
kidney
eye
skin
brain
gastrointestin
tract
follow
death
bcg
vaccin
two
affect
commun
discontinu
recent
advent
target
newborn
screen
homozyg
ikbkb
mutat
two
affect
commun
bcg
vaccin
birth
held
result
newborn
screen
confirm
infant
affect
one
patient
met
clinic
laboratori
criteria
hemophagocyt
lymphohistiocytosi
hlh
although
possibl
addit
patient
would
met
hlh
criteria
unrecogn
despit
connect
ikbkb
ikknemo
complex
none
patient
exhibit
ectoderm
dysplasia
one
patient
document
organ
abnorm
dysplast
kidney
time
autopsi
sixteen
ikbkb
immun
defici
patient
eight
die
overwhelm
infect
hsct
could
perform
eight
proceed
hsct
detail
autopsi
report
avail
three
die
prior
hsct
asid
evid
infect
exhibit
sever
thymic
hypoplasia
scant
lymphoid
cell
popul
minim
lymph
node
tonsillar
tissu
absenc
germin
follicl
spleen
rang
immunolog
test
perform
time
extent
type
test
depend
upon
year
present
initi
suspicion
immunodefici
diagnosi
extens
immunolog
investig
like
occur
contemporari
era
median
total
lymphocyt
count
time
diagnosi
l
rang
l
patient
exhibit
normal
n
elev
n
total
lymphocyt
count
age
three
lymphopen
infant
sever
infect
dissemin
bcg
two
klebsiella
sepsi
one
time
initi
blood
work
perform
along
variou
lymphocyt
subset
hematolog
cytopenia
anemia
thrombocytopenia
consist
bone
marrow
suppress
infect
median
tcell
count
patient
rang
cell
one
patient
tcell
count
tcell
prolif
respons
avail
patient
fig
rel
control
three
pha
respons
two
pha
respons
eight
pha
respons
rang
relat
evid
pha
respons
total
tcell
count
although
two
patient
sever
tcell
lymphopenia
dissemin
bcg
pha
respons
two
infant
identifi
birth
without
infect
normal
pha
respons
trec
perform
six
infant
normal
trec
express
level
pbmc
copi
extens
tcell
immun
phenotyp
perform
three
patient
exhibit
preponder
tcell
tcell
popul
tcell
tcell
popul
minim
central
effector
memori
tcell
present
case
one
patient
tcr
vbeta
repertoir
perform
reveal
normal
polyclon
tcell
popul
eight
patient
underw
hsct
use
either
bone
marrow
human
leukocyt
antigen
match
parent
sibl
n
unrel
umbil
cord
blood
n
graft
sourc
tabl
two
patient
initi
receiv
condit
regimen
patient
due
critic
ill
infect
fail
engraft
second
transplant
perform
one
use
myeloabl
condit
result
subsequ
engraft
condit
regimen
initi
use
six
two
patient
one
receiv
reduc
intens
condit
regimen
follow
cord
blood
transplant
initi
engraft
experienc
secondari
graft
failur
two
year
posthsct
four
patient
receiv
busulfanbas
myeloabl
condit
regimen
busulfan
pharmacokinet
monitor
either
full
mix
donor
chimer
gener
favor
myeloid
engraft
three
patient
receiv
transplant
remain
aliv
posthsct
two
patient
die
soon
hsct
day
complic
relat
infect
present
time
transplant
three
other
die
new
infect
acquir
posthsct
includ
two
patient
die
dissemin
mycobacterium
aviumintracellulair
infect
associ
secondari
graft
failur
posthsct
third
patient
die
streptococcu
pneumonia
bacteremia
mening
despit
full
donor
chimer
posthsct
new
clinic
relev
infect
includ
viral
bacteri
fungal
mycobacteri
infect
common
patient
surviv
least
transplant
still
occur
year
transplant
despit
full
mix
lymphoid
myeloid
donor
chimer
normal
neutrophil
lymphocyt
count
infect
includ
streptococcu
pneumonia
bacteremia
n
mening
n
osteomyel
n
septic
arthriti
n
staphylococcu
aureu
bacteremia
cellul
osteomyel
n
salmonella
bacteremia
enterocol
n
pseudomona
aeruginosa
bacteremia
n
viral
infect
eg
influenza
parainfluenza
varicella
adenoviru
also
occur
resolut
patient
one
patient
develop
mycobacteri
tuberculosi
pneumonia
posthsct
success
treat
antituberculosi
medic
remain
longterm
survivor
patient
achiev
normal
number
cell
posthsct
immunoglobulin
replac
variabl
patient
gener
continu
posthsct
pha
respons
normal
patient
despit
find
specif
antibodi
product
posttranspl
vaccin
immunoglobulin
discontinu
poor
instanc
patient
make
antipneumococc
fig
phytohemagglutinin
respons
time
ikbkb
diagnosi
patient
number
percent
control
defin
stimul
index
patient
rel
averag
stimul
index
two
healthi
control
correspond
tcell
count
time
diagnosi
patient
number
patient
dissemin
bcg
bone
marrow
involv
sever
cytopenia
includ
lymphopenia
may
impact
pha
respons
hematopoiet
stem
cell
transplant
outcom
ikbkb
immun
defici
patient
detail
autopsi
report
avail
patient
hsct
asid
evid
infect
exhibit
sever
thymic
hypoplasia
scant
lymphoid
cell
popul
minim
lymph
node
tonsillar
tissu
absenc
germin
follicl
spleen
patient
experienc
secondari
graft
failur
posthsct
develop
dissemin
mycobacterium
aviumintracellulair
manag
antitubercul
medic
splenectomi
death
spleen
entir
replac
atyp
mycobacteria
autopsi
perform
hsct
thymu
small
atroph
weigh
g
lymph
node
readili
appar
seri
present
clinic
featur
immunolog
present
hsct
outcom
largest
cohort
ikbkb
immun
defici
patient
publish
date
number
import
conclus
made
first
clinic
present
case
seri
indic
ikbkb
immun
defici
result
profound
defect
innat
adapt
immun
manifest
except
suscept
varieti
differ
sever
infect
includ
bacteria
virus
fungi
mycobacteria
believ
ikbkb
immun
defici
although
meet
convent
laboratorybas
diagnost
criteria
scid
due
higher
tcell
count
moder
decreas
normal
pha
respons
normal
trec
high
proport
tcell
low
tcell
ikbkb
immun
defici
sever
immun
defici
scid
clinic
level
would
suggest
therefor
inclus
ikbkb
defici
descript
categori
combin
immun
defici
gener
less
profound
scid
recent
intern
union
immunolog
societi
classif
like
underestim
sever
immun
defici
modifi
futur
iter
support
profound
immun
defici
six
report
patient
ikbkb
mutat
also
present
sever
bacteri
fungal
viral
infect
young
infant
mycobacteri
infect
also
promin
dissemin
bcg
note
four
six
similar
cohort
previous
report
ikbkb
immun
defici
patient
exhibit
normal
elev
absolut
tcell
bcell
number
low
memori
tcell
absent
low
classswitch
memori
bcell
immunoglobulin
univers
low
undetect
prolif
respons
pha
present
typic
normal
one
patient
note
featur
ectoderm
dysplasia
older
age
month
featur
seen
three
posthsct
survivor
two
report
patient
die
overwhelm
infect
prior
definit
therapi
four
receiv
hsct
one
longterm
survivor
secondli
data
expand
understand
primari
immun
defici
involv
aberr
signal
least
patient
germlin
gain
function
mutat
nfkbia
report
sever
variabl
clinic
immun
phenotyp
appear
depend
upon
genotyp
missens
mutat
result
sever
clinic
phenotyp
like
ikbkb
immun
defici
patient
hypermorph
nfkbia
mutat
result
reduc
degrad
present
multipl
sever
bacteri
fungal
viral
infect
start
earli
age
typic
infect
report
includ
invas
bacteria
klebsiella
pseudomona
haemophilu
influenza
staphylococcu
aureu
mycobacteria
includ
vaccinestrain
bcg
well
chronic
mucocutan
candidiasi
pneumocysti
pneumon
sever
viral
infect
rotaviru
noroviru
parainfluenza
rsv
cmv
similarli
patient
nfkbia
mutat
present
normal
elev
tcell
count
excess
cell
normal
mitogen
prolif
respons
pha
dysgammaglobulinemia
usual
one
quantit
abnorm
immunoglobulin
isotyp
impair
respons
vaccin
antigen
test
absent
reduc
memori
bcell
class
switch
memori
bcell
also
report
unlik
patient
ikbkb
immun
defici
howev
almost
patient
defect
show
degre
ectoderm
dysplasia
comparison
individu
hemizyg
hypomorph
ikbkg
mutat
reduc
nemo
express
manifest
variabl
clinic
immunolog
phenotyp
compar
patient
ikbkb
immun
defici
hypermorph
nfkbia
mutat
addit
infecti
predisposit
patient
nemo
defici
may
present
autoimmun
inflammatori
condit
notabl
inflammatori
bowel
diseas
featur
describ
either
cohort
ikbkb
immun
defici
patient
hypermorph
defect
patient
ikbkb
immun
defici
patient
nemo
defici
commonli
present
infect
due
pyogen
bacteria
mycobacteria
virus
fungal
opportunist
pathogen
median
age
hsct
larg
cohort
nemo
defici
patient
year
old
rang
month
year
age
older
compar
cohort
suggest
nemo
defici
may
less
sever
immun
defici
rel
ikbkb
immun
defici
nemo
defici
also
variabl
immunolog
phenotyp
hypogammaglobulinemia
defect
specif
antibodi
product
similar
ikbkb
immun
defici
patient
nemo
defici
normal
elev
count
normal
mitogen
induc
prolifer
third
import
find
studi
scid
newborn
screen
trec
assay
detect
ikbkb
immun
defici
given
sever
clinic
phenotyp
ikbkb
immun
defici
pilot
project
target
newborn
screen
direct
genet
mutat
analysi
guthri
card
ikbkb
mutat
develop
select
northern
cree
commun
manitoba
investig
identifi
carrier
frequenc
newborn
predict
mutat
homozygos
birth
newborn
two
commun
screen
one
infant
identifi
birth
patient
subsequ
sibl
patient
identifi
inutero
place
protect
isol
birth
receiv
hsct
earli
age
onset
seriou
infect
import
variabl
associ
excel
outcom
scid
hsct
popul
founder
mutat
high
rate
consanguin
similar
geneticbas
newborn
screen
strategi
might
applic
unfortun
patient
later
die
invas
streptococcu
pneumonia
infect
home
commun
follow
otherwis
success
transplant
illustr
complex
interplay
suspect
ongo
defect
immun
posthsct
combin
poor
social
determin
health
famili
cultur
reason
patient
often
strong
desir
return
home
soon
hsct
tertiari
care
hsct
center
easili
access
remot
commun
death
patient
recent
transplant
patient
institut
program
hous
famili
close
tertiari
care
center
least
year
posthsct
well
regular
immunoglobulin
replac
indefinit
daili
antipneumococc
antibiot
prophylaxi
much
remain
unknown
immun
abnorm
patient
ikbkb
immun
defici
hsct
previou
investig
broad
immun
defect
relat
abnorm
signal
tcell
bcell
innat
immun
cell
result
gener
activ
defect
varieti
stimuli
except
regulatori
tcell
gammadelta
tcell
absent
ikbkb
immun
defici
lymphocyt
subset
appear
develop
normal
despit
thymic
hypoplasia
five
patient
die
either
prior
hsct
six
patient
normal
trec
level
time
diagnosi
suggest
intrins
defect
tcell
develop
matur
within
thymu
unfortun
none
patient
autopsi
perform
detail
trec
analysi
make
direct
correl
underdevelop
thymu
trec
level
singl
patient
imposs
detail
tcell
studi
avail
patient
prehsct
previous
studi
one
patient
one
addit
patient
seri
tcell
receptor
betachain
variabl
region
repertoir
polyclon
unabl
resolv
appar
contradict
autopsi
immunolog
find
believ
warrant
studi
likewis
studi
two
patient
kappadelet
recombin
excis
circl
krec
dri
blood
spot
newborn
guthri
card
two
patient
found
normal
suggest
normal
b
cell
develop
mous
model
involv
hypermorph
mutat
signal
nonimmun
architectur
cell
shown
sever
disrupt
although
cell
deriv
hematopoiet
stem
cell
nonetheless
integr
lymphoid
organogenesi
develop
lymph
node
peyer
patch
splenic
margin
zone
follicular
dendrit
cell
format
germin
center
spleen
absent
immun
defect
model
fulli
correct
hsct
reason
suspect
therefor
similar
architectur
cell
dysfunct
result
disrupt
immunolog
nich
could
also
play
role
ikbkb
immun
defici
failur
correct
nonimmun
cell
hsct
could
explain
ongo
infecti
complic
seen
year
otherwis
appar
success
lymphoid
engraft
transplant
ikbkb
immun
defici
absenc
splenic
germin
center
lack
tonsil
lymphoid
tissu
autopsi
patient
die
posthsct
absent
specif
vaccin
respons
despit
excel
donor
tand
bcell
chimer
support
hsct
fulli
correct
aspect
immun
defici
ikbkb
year
past
patient
profoundli
ill
present
full
immun
evalu
alway
avail
elucid
natur
immun
defici
popul
moment
three
survivor
cohort
detail
cell
studi
preand
posthsct
includ
serial
measur
cell
marker
recent
thymic
emigr
marker
naiveti
memori
cell
marker
activ
exhaust
limit
date
move
forward
geneticbas
newborn
screen
introduc
condit
provinc
opportun
despit
challeng
believ
ikbkb
immun
defici
still
disord
requir
hsct
knowledg
individu
longterm
survivor
ikbkb
immun
defici
without
hsct
unawar
report
hypomorph
ikbkb
mutat
produc
milder
clinic
phenotyp
allow
clinician
take
wait
see
approach
hsct
disord
involv
pathway
previous
describ
includ
hemizyg
hypomorph
ikbkg
mutat
hypermorph
nfkbia
mutat
cohort
fourteen
gain
function
patient
report
boisson
et
al
eleven
receiv
hsct
five
survivor
one
patient
die
without
receiv
hsct
two
patient
surviv
without
receiv
hsct
sinc
center
genet
base
newborn
screen
ikbkb
immun
defici
clinician
would
like
face
infant
present
sever
lifethreaten
infect
given
trec
base
newborn
screen
detect
disord
commerci
avail
nextgener
sequenc
gene
panel
immun
defici
disord
includ
mani
scid
panel
increasingli
includ
ikbkb
facilit
diagnosi
although
alway
time
manner
hsct
seri
two
three
patient
surviv
hsct
seriou
lifethr
infect
transplant
includ
case
multipl
serratia
marcescen
intracerebr
abscess
longterm
neurocognit
outcom
initi
unclear
tend
aggress
antimicrobi
support
care
measur
goal
reach
hsct
quickli
possibl
strategi
result
longterm
surviv
infant
receiv
hsct
activ
infect
said
suspect
surviv
significantli
improv
current
newborn
screen
strategi
absenc
prehsct
infect
unfortun
base
limit
dataset
believ
myeloabl
condit
may
requir
engraft
ikbkb
immun
defici
largest
recent
studi
hsct
nemo
patient
howev
find
necessarili
true
cohort
fifteen
patient
receiv
classic
myeloabl
condit
thirteen
patient
receiv
reduc
intens
condit
global
engraft
rate
similar
surviv
rate
secondari
graft
failur
rate
independ
condit
regimen
intens
center
current
use
daili
intraven
dose
busulfan
day
aim
area
curv
approxim
min
fludarabin
mgkgdose
day
rabbit
antithymocyt
globulin
mgkgdose
day
acknowledg
condit
regimen
might
also
efficaci
although
caution
late
secondari
graftfailur
appear
concern
ikbkb
immun
defici
final
importantli
clinician
mind
despit
appar
reason
basic
laboratori
immun
reconstitut
data
ikbkb
immun
defici
patient
posthsct
eg
tcell
count
chimer
studi
late
infect
includ
bacteri
mycobacteri
infect
particular
appear
common
interest
one
longterm
survivor
fulli
engraft
develop
primari
mycobacterium
tuberculosi
pulmonari
diseas
posthsct
appropri
therapi
infect
resolv
suggest
hsct
correct
enough
immun
defici
contrast
posthsct
patient
ikbkb
immun
defici
miot
et
al
found
bacteri
infect
recur
posthsct
nemo
defici
patient
hypothes
failur
hsct
improv
aspect
innat
adapt
immun
function
transplant
shown
number
ongo
seriou
bacteri
mycobacteri
infect
lack
protect
specif
antibodi
respons
vaccin
could
hsct
correct
cell
nonhematopoiet
origin
import
immun
respons
also
depend
upon
signal
similar
pattern
incomplet
immun
correct
ongo
bacteri
viral
infect
hsct
report
patient
relat
autosom
domin
anhidrot
ectoderm
dysplasia
immun
defici
due
hypermorph
defect
summari
present
rel
larg
cohort
rare
primari
immunodefici
disord
ikbkb
immun
defici
character
presenc
tcell
evid
function
activ
defect
amen
hsct
although
ongo
longterm
infecti
challeng
